STSA increasing 7% today. Here's what's moving the stock:

Satsuma Pharmaceuticals Inc (STSA) is trading 7% higher at $6.41 today. So far the Health Care sector has been having a somewhat glum day, and the share price of the company is quickly outperforming it's peers.

The stock seems to be rated favorably by analysts as it breaks out to near 52 week highs today. The company is heavily institutionally owned, and reported earnings earlier this month with a EPS of -$0.52.

Satsuma Pharmaceuticals Inc has been trading between a 52-week high of $6.52 and a 52-week low of $2.51. The stock has a market cap of $202 Million.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients.